Skip to content Skip to footer
Subscribe Now
NEWS

Eli Lilly Acquires Engage Biologics for ~$202M

Shots: Eli Lilly has acquired Engage Biologics, combining Engage’s Tethosome platform with Lilly’s genetic medicines capabilities & portfolio As per the deal, Eli Lilly acquired Engage for ~$202M in cash, incl. an upfront payment and subsequent development milestones payments The Tethosome platform is a non-viral DNA delivery system that combines engineered DNA payloads, lipid nanoparticles,…
May 21, 2026

Read more

NEWS

Incyte Expands Partnership with Genesis Molecular AI to Advance AI-Driven Drug Discovery

Shots: Incyte and Genesis have expanded their collaboration to accelerate the discovery of novel molecules for Incyte-selected targets by deploying Genesis’ GEMS molecular AI platform across a broader range of challenging targets in Incyte’s portfolio Incyte will provide experimental data to enhance GEMS’ capabilities, plus the companies will add ≥5 new targets, with options for…
May 21, 2026

Read more

NEWS

QIAGEN Teams Up with NVIDIA to Advance AI-Driven Drug Discovery

Shots: QIAGEN to integrate its Digital Insights bioinformatics business with NVIDIA accelerated computing & the NVIDIA BioNeMo platform to strengthen AI applications in drug discovery Partnership leverages graph-based AI that apply retrieval & reasoning techniques across biomedical knowledge graphs to help researchers analyze complex biological data & validate AI-generated insights, supporting practical applications across the…
May 20, 2026

Read more

NEWS

Sensome Reports the INSPECT Study Results of its In Situ Tumor Detection Technology for Lung Cancer

Shots: Sensome has reported results from its INSPECT study assessing its microsensor technology integrated into a smart stylet for bronchoscopic lung biopsy in 27 pts across Australia & France In the study, the smart stylet was inserted into the biopsy needle to capture tissue readings immediately before biopsy, with histopathology confirming measurement accuracy & cross-validating…
May 20, 2026

Read more

NEWS

Samsung Bioepis Introduces its Ustekinumab Biosimilar in Japan with NIPRO CORPORATION

Shots: Samsung Bioepis has reported the launch of Ustekinumab BS 45 mg Syringe for SC Injection 「NIPRO」, a biosimilar version of Stelara, in Japan, marking the company’s first commercialized product in the country The biosimilar will be commercialized by NIPRO CORPORATION under a strategic partnership between Samsung Bioepis & NIPRO in 2025, focused on developing &…
May 20, 2026

Read more

GSK
NEWS

GSK Receives MHLW Approval for Arexvy to Prevent Respiratory Syncytial Virus (RSV) Disease

Shots: The Japanese MHLW has approved GSK's Arexvy RSV vaccine for adults (18-49yrs.) at increased risk for RSV disease, expanding its use beyond those aged ≥50yrs. Approval was based on P-IIIb trial (n=1458) assessing Arexvy in individuals (18-49yrs.; n=426) compared to adults (≥60yrs.; n=429), which showed a non-inferior immune response in individuals (18-49yrs.) who are at increased…
May 19, 2026

Read more

Load more